Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 5/20 | 0.52 |
| ▸ | SRC | P12931 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 7/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | BCR | P11274 | 3/20 | 0.49 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12432449 | 0.96 | CSF1R (0.58) | CSF1RKDM4EPOLBRECQLABL1 | |
| SCHEMBL12433869 | 0.94 | CSF1R (0.57) | CSF1RKDM4EPOLBRECQLABL1 | |
| SCHEMBL2358403 | 0.92 | BRAF (0.52) | CSF1RKDM4EPOLBRECQLABL1 | |
| SCHEMBL14717063 | 0.90 | ABL1 (0.52) | CSF1RKDM4EPOLBRECQLABL1 | |
| SCHEMBL14716921 | 0.90 | CSF1R (0.63) | CSF1RABL1SRCBRAFRAF1 | |
| SCHEMBL2358401 | 0.90 | BRAF (0.46) | CSF1RKDM4EPOLBRECQLABL1 | |
| SCHEMBL14717736 | 0.89 | ABL1 (0.53) | CSF1RKDM4EPOLBRECQLABL1 | |
| SCHEMBL12433475 | 0.89 | ABL1 (0.63) | ABL1SRCBRAFBCRRAF1 | |
| SCHEMBL12432634 | 0.89 | BRAF (0.60) | CSF1RABL1SRCBRAFRAF1 | |
| SCHEMBL12433483 | 0.88 | CSF1R (0.62) | CSF1RKDM4EPOLBRECQLABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | claimed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | claimed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | claimed |
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | disclosed |
| EP-2528925-B1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO LTD (KR) | 2017-07-05 | — | — | EP | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-8999973-B2 | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases | HANMI SCIENCE CO., LTD (KR) | 2015-04-07 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | HANMI SCIENCE CO., LTD. (KR) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053370-A1 | THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES | CDK2, TK1, DTYMK | CSF1R 3387/4885KDM4E 2448/4885POLB 1235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.